胸腹主动脉瘤腔内治疗患者基于脑脊液引流策略的住院趋势
该单中心回顾性研究纳入2008至2023年接受择期开窗分支腔内修复术(FB-EVAR)的412例I至IV型胸腹主动脉瘤患者,按脑脊液引流(CSFD)策略分为2020年前预防性引流组与2020年后治疗性引流组。结果显示住院时间从9±9天降至6±5天(P=.02),脊髓缺血发生率无显著差异(7.6% vs 4.9%,P=.627),ICU住院时间相似(3±3 vs 2.5±3天,P=.19)。
要点
- 预防性CSFD使用率从70%降至1.2%(P<.001),同期住院时间从9±9天降至6±5天(P=.02)。
- 脊髓缺血发生率两组无显著差异(7.6% vs 4.9%,P=.627),ICU住院时间相似(3±3 vs 2.5±3天,P=.19)。
- 调整混杂因素后,CSFD策略转变是住院时间缩短的唯一可干预独立危险因素(P=.01)。
核心结论
- 在胸腹主动脉瘤FB-EVAR患者中,从预防性CSFD转为治疗性CSFD策略后住院时间缩短,且未增加脊髓缺血,ICU住院时间相似。
研究设计与样本
- 单中心回顾性研究,纳入2008至2023年接受择期FB-EVAR的I至IV型胸腹主动脉瘤患者412例,按CSFD策略分为2020年前预防性引流组(Group 1)和2020年后治疗性引流组(Group 2)。
主要发现
- 平均年龄73±8岁,68%为男性;252例(61%)使用患者定制器械,110例(27%)使用医生改良内移植物,50例(12%)使用即用型器械。
- Group 1平均住院时间9±9天 vs Group 2 6±5天(P=.02),预防性CSFD使用率70% vs 1.2%(P<.001)。
- 脊髓缺血发生率Group 1 7.6% vs Group 2 4.9%(P=.627),ICU住院时间Group 1 3±3天 vs Group 2 2.5±3天(P=.19)。
- Group 2较Group 1充血性心力衰竭(24% vs 11%,P=.003)、高胆固醇血症(91% vs 80%,P=.015)、慢性阻塞性肺疾病(55% vs 37%,P=.004)及外周动脉疾病(39% vs 19%,P<.001)发生率更高。
- 调整美国麻醉医师协会评分、合并症及器械类型后,住院时间差异仍具统计学显著性(P=.01)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to identify trends in hospital length of stay (HLOS) and intensive care unit length of stay (ICULOS), and the relationship with cerebrospinal fluid drainage (CSFD) protocols in patients undergoing fenestrated-branched endovascular aortic repair (FB-EVAR) of thoracoabdominal aortic aneurysms (TAAAs). METHODS: A retrospective review of patients who underwent elective FB-EVAR for extent I to IV TAAAs between 2008 and 2023 at a single aortic center of excellence was conducted. Patient demographics, cardiovascular comorbidities, surgical risk, technical details, CSFD strategy (prophylactic or therapeutic), procedural success, and perioperative outcomes were collected. Patients were divided into two groups based on CSFD protocol. Group 1 included patients treated before 2020 when prophylactic CSFD was performed widely, and Group 2 consisted of patients treated since 2020 with therapeutic CSFD. Primary end points were HLOS, ICULOS, major adverse events, and perioperative mortality. RESULTS: FB-EVAR was performed in 702 patients; 412 underwent elective TAAA repair and were included in the analysis. Mean age was 73 ± 8 years and 68% were male. Patient-specific manufactured devices were used in 252 patients (61%), physician-modified endografts in 110 (27%), and 50 patients (12%) were treated with off-the-shelf devices. Demographics, aneurysm extent, major adverse events (including spinal cord ischemia [SCI]), and mortality were similar in both groups. A significant reduction in mean HLOS between the groups (9 ± 9 vs 6 ± 5 days; P = .02) coincided with decreased use of prophylactic CSFD (70% vs 1.2%; P < .001), with similar rates of SCI (7.6% vs 4.9%; P = .627) and ICULOS (3 ± 3 vs 2.5 ± 3; P = .19). Patients in the therapeutic drainage cohort (group 2) had a higher incidence of congestive heart failure (24% vs 11%; P = .003), hypercholesterolemia (91% vs 80%; P = .015), chronic obstructive pulmonary disease (55% vs 37%; P = .004), and peripheral artery disease (39% vs 19%; P < .001) compared with group 1, suggesting treatment of a more complex patient cohort. On adjusted multivariable analysis accounting for American Society of Anesthesiologists score, comorbidities, and device type, the difference in HLOS remained statistically significant (P = .01). CONCLUSIONS: HLOS decreased over time in patients undergoing FB-EVAR for TAAA after transition from a prophylactic to a therapeutic CSFD protocol. This transition was the only modifiable, independent risk factor for a shorter HLOS, without an increase in SCI, albeit with similar ICULOS.
引用
- Rodrigues DVS, Chait J, Cirillo-Penn NC, et al. Trends in hospitalization of patients undergoing endovascular treatment of thoracoabdominal aortic aneurysms based on cerebrospinal fluid drainage strategy. J Vasc Surg. 2024. PMID: 38768834. doi:10.1016/j.jvs.2024.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。